POLYSAN Scientific & Technological Pharmaceutical Company clinical trials
The registry lists 23 studies whose lead sponsor is POLYSAN Scientific & Technological Pharmaceutical Company. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 21, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 23studies on the registry
- 4open to participants now
- 1phase 3 study under way
Get an email when these change. Save the POLYSAN Scientific & Technological Pharmaceutical Company studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 1 programme
Each counted once: 1 with a study POLYSAN Scientific & Technological Pharmaceutical Company leads registered in the last two years.
- Phase 3
The 1 phase-3 programme — sign in to see them, free: with every programme, filter by condition or phase and sort by first study or primary completion.
The 1 programme — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or primary completion.
“Registry” is the highest phase of POLYSAN Scientific & Technological Pharmaceutical Company’s own registered studies; POLYSAN Scientific & Technological Pharmaceutical Company’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs POLYSAN Scientific & Technological Pharmaceutical Company’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- cytoflavin4 in phase 30 open · 4
- Ringer's Solution2 in phase 30 open · 2
- 0 open · 1
All 23 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 16
- 17
- 18
- 19
- 20
- 21
- 422
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to POLYSAN Scientific & Technological Pharmaceutical Company.
- POLYSAN Scientific & Technological Pharmaceutical Company23 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years OldRecruitingNCT07066540
- REAMBERIN® 1.5% in Rehydration Therapy of Diabetic KetoacidosisRecruitingNCT06955416Phase 2/3
- Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion TherapyRecruitingNCT06514976
- Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care SyndromeRecruitingNCT06735898
- Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive JaundiceCompletedNCT05928286
- Cytoflavin in the Complex Rehabilitation of Stroke PatientsCompletedNCT05935787Phase 3
- Remaxol® in Patients With Drug-induced Liver Injuries During Cancer ChemotherapyCompletedNCT05789797
- Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and InfluenzaCompletedNCT06183229Phase 3
- Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic CholestasisCompletedNCT06183242Phase 2/3
- Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol IntoxicationCompletedNCT05715723
- International Trial of Efficacy of Cytoflavin in Head TraumaCompletedNCT04631484Phase 3
- Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19CompletedNCT05172180
- Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral InfectionCompletedNCT06286254
- Cytoflavin in the Rehabilitation of Post-intensive Care Syndrome in Stroke SurvivorsCompletedNCT04194229
- Cytoflavin in Combination With Reperfusion in Stroke PatientsCompletedNCT05297851
- Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major SurgeryCompletedNCT03849664Phase 3
- Cytoflavin in the Treatment of Patients With Diabetic PolyneuropathyCompletedNCT04649203Phase 3
- Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill PatientsCompletedNCT05147051Phase 2
- Remaxol® in Mechanical Jaundice of Non-malignant OriginCompletedNCT03418935Phase 3
- Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy VolunteersCompletedNCT03028285Phase 1
- Remaxol® in Malignant Mechanical JaundiceCompletedNCT03416062Phase 3
- "Unifuzol®" in Patients With Peripheral Arterial DiseaseCompletedNCT03861416Phase 2
- Runihol in Nonalcoholic Fatty Liver Disease and Metabolic SyndromeTerminatedNCT02930161Phase 2